Ethylenimines
Thiotepa, an
ethylenimine derivative, is a multifunctional alkylat-ing drug.
After I.V. administration, thiotepa is 100%
bioavailable. Significant systemic absorption may occur when thiotepa is
administered into pleural (around the lungs) or peritoneal (abdominal) spaces
to treat malignant effusions or is instilled into the bladder.
Thiotepa crosses the blood-brain barrier and is
metabolized exten-sively in the liver. Thiotepa and its metabolites are
excreted in urine.
Thiotepa exerts its cytotoxic activity by
interfering with DNA replication and RNA transcription. Ultimately, it disrupts
nucleic acid function and causes cell death.
Thiotepa is used to treat bladder cancer. This
alkylating drug is also prescribed for palliative (symptom-relief) treatment of
lym-phomas and ovarian or breast cancers.
Thiotepa is used for the treatment of
intracavitary effusions (accu-mulation of fluid in a body cavity). It may also
prove useful in the treatment of lung cancer.
Thiotepa may interact with other drugs.
·
Concurrent use of thiotepa, anticoagulants, and aspirin may in-crease
the risk of bleeding.
·
Taking thiotepa with neuromuscular blocking drugs may pro-long muscular
paralysis.
·
Concurrent use of thiotepa and other alkylating drugs or radia-tion
therapy may intensify toxicity rather than enhance the thera-peutic response.
When used with succinylcholine, thiotepa may cause
prolonged respirations and apnea (periods of not breathing). Thiotepa ap-pears
to inhibit the activity of cholinesterase, the enzyme that de-activates
succinylcholine. (See Adverse reactions
to thiotepa.)
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.